secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2026-08-14T12:30:52+00:00
Accession:  0001140361-26-032951
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics-Vertex merger clears HSR and key antitrust hurdles; close expected early Sept
--------------------------------------------------------------------------------

- HSR waiting period expired Aug 12, 2026 at 12:45 p.m. ET.
- Antitrust approvals received in Austria, Germany, Australia; Australia waiting period expires Aug 27, 2026.
- Shareholder vote scheduled for Aug 28, 2026; merger expected to close early September 2026.
- Deal projected to support >$5B annual revenue and be accretive to non-GAAP operating income in 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000114036126032951/0001140361-26-032951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000114036126032951/ef20080199_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-032951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer